Clinical Research Directory
Browse clinical research sites, groups, and studies.
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
Sponsor: Beijing Tongren Hospital
Summary
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B- NHL. In this prospective phase 2 clinical trial, the investigators aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory Large B cell lymphoma.
Official title: CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma: A Prospective, Single-Arm, Single-Center, Phase 2 Trial
Key Details
Gender
All
Age Range
14 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2022-02-01
Completion Date
2027-12-31
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
CD19/CD22 bispecific CAR-T cells
CD19/CD22-bispecific CAR-T cells were infused at the dosage of 2×10e6/kg
Locations (1)
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China